NCT05397496
Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies
At risk: Primary completion moved at least 4 months later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 40 versions: 39 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 15 words
- Primary and study completion pushed from Jan 4, 2027 to May 31, 2027
- Secondary endpoints: details revised at 6 of 12 entries
- Site details revised at 1 of 18 sites
- Minor Primary and study completion pushed from Aug 20, 2026 to Jan 4, 2027v39
- Minor Primary and study completion pushed from Jul 16, 2026 to Aug 20, 2026v38
- Minor Primary and study completion pushed from May 14, 2026 to Jul 16, 2026
- Site details revised at 1 of 18 sites
- Notable Primary and study completion dates moved earlier to May 14, 2026v36
Show 33 earlier versionsHide 33 earlier versions
- Minor Enrollment target: estimated 140 to confirmed 61
- Study sites: 19 to 18
- Minor Trial status: Recruiting to Active, Not Recruiting
- Study sites: 21 to 19
- Minor Study sites: 20 to 21v33
- Minor Study sites: 19 to 20v32
- Minor Study sites: 18 to 19v31
- Minor Study sites: 17 to 18v30
- Minor Study sites: 16 to 17v29
- Minor Study sites: 15 to 16v28
- Minor Study sites: 16 to 15v27
- Minor Study sites: 15 to 16v26
- Minor Study sites: 14 to 15v25
- Minor Site details revised at 3 of 14 sitesv24
- Notable Eligibility criteria shortened, about 6 words
- Study sites: 11 to 14
- Study description shortened, about 22 words
- Minor Study sites: 13 to 11v22
- Minor Study sites: 12 to 13v21
- Minor Site details revised at 2 of 12 sitesv20
- Minor Study sites: 11 to 12v19
- Notable Primary completion date: Feb 28, 2025 to Jun 7, 2027
- Study completion date: Feb 27, 2026 to Jun 5, 2028
- Minor Study sites: 10 to 11v17
- Minor Study sites: 9 to 10v16
- Minor Study sites: 8 to 9v15
- Minor Study sites: 7 to 8v14
- Minor Study sites: 6 to 7v13
- Minor Study sites: 5 to 6v12
- Notable Primary completion date: Aug 22, 2024 to Feb 28, 2025
- Study completion date: Aug 21, 2025 to Feb 27, 2026
- Minor Study sites: 4 to 5v10
- Minor Study sites: 2 to 4
- Primary completion date: Jun 13, 2024 to Aug 22, 2024
- Minor Study completion date: Jun 12, 2025 to Aug 21, 2025v8
- Minor Start date changed from estimate of Oct 24, 2022 to Oct 3, 2022v6
- Notable Start date: Sep 12, 2022 to Oct 24, 2022v5
- Minor Study sites: 1 to 2v4
Notable Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
- Study sites: 0 to 1
- Primary completion date: Jun 3, 2024 to Jun 13, 2024
- Study completion date: Jun 2, 2025 to Jun 12, 2025
- Start date: Aug 31, 2022 to Sep 12, 2022
- Notable Start date: Jul 29, 2022 to Aug 31, 2022
- Primary completion date: May 1, 2024 to Jun 3, 2024
- Study completion date: Apr 30, 2025 to Jun 2, 2025
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (12)
Show 7 moreShow less
Arms and interventions
PIT565 in adult NHL patients for whom two or more lines of chemotherapy have failed and either having progressed (or relapsed) after autologous hematopoietic stem cell transplantation (HSCT), or being ineligible for or not consenting to the procedure
PIT565 in adult R/R ALL patients.
PIT565 Recommended dose 1 (RD1) in adult R/R large B-cell lymphoma (LBCL) (DLBCL, double/triple hit High-grade B-cell lymphoma (HGBCL), Primary mediastinal large B-cell lymphoma (PMBCL), Follicular lymphoma grade 3B (FL3B)) patients.
PIT565 RD2 in adult R/R LBCL (DLBCL, double/triple hit HGBCL, PMBCL, FL3B) patients.
PIT565 in adult R/R ALL patients.
Biologicals: PIT565
Sites
18 sites in 9 countries
United States 5, China 3, France 2, Singapore 2, Spain 2, Belgium 1, Israel 1, Italy 1, Japan 1